PARP inhibitors in advanced prostate cancer: when to use them?

Abstract excerpt

Poly (ADP-ribose) polymerase (PARP) inhibitors have antitumor activity in advanced prostate cancer associated with loss of homologous recombination repair (HRR) function. About 20% of all patients with advanced prostate cancer present germline or tumor mutations in HRR-related genes, the most common being BRCA2, mutated in approximately 10% of all advanced prostate cancers. Challenges related to sample...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Repair
• Share to Mutation
• Share to Poly(ADP-ribose) Polymerase Inhibitors